Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2014 Jun 17;32(29):3680-6. doi: 10.1016/j.vaccine.2014.04.031. Epub 2014 May 14.

Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection.

Author information

1
Instituto Nacional de Salud Pública, Cuernavaca, México. Electronic address: jdiaz@insp.mx.
2
Retired from Centers for Disease Control and Prevention, Atlanta, GA, USA.
3
Instituto Nacional de Salud Pública, Cuernavaca, México.
4
Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, México.

Abstract

IMPORTANCE:

Aerosol immunization may be a useful tool to reach and sustain the elimination of measles, rubella, and congenital rubella syndrome. We compared booster seroresponses to aerosolized or injected MMR vaccines containing different strains of measles (Attenuvax or Edmonston-Zagreb) and mumps (Jeryl-Lynn or Leningrad-Zagreb).

OBJECTIVE:

To assess the safety and immunogenicity of two MMR: Vaccines administered by aerosol.

METHODS:

A randomized and controlled clinical trial was conducted to evaluate the safety and booster responses to the MMR SII (Serum Institute of India) and MMR II (Merck Sharp & Dhome) vaccines, both of which were administered by aerosol (ae) or injection (inj) to Mexican children aged 6-7 years in elementary schools. The seroresponses were evaluated by PRN (measles) and ELISA (rubella and mumps). Adverse events were followed-up for 28 days after the immunization.

RESULTS:

Two hundred and fifty-three of 260 children completed the one-month follow-up. All participants reached protective seropositivity for measles and rubella after immunization, and 98.3 to 100% reached protective seropositivity for mumps (p=0.552). The proportions of the seroresponses (a 2-fold rise from the baseline antibody titers) to measles were 38.3% for MMR SII (ae), 31.3% for MMR II (ae), 37.5% for MMR SII (inj), and 44.6% for MMR II (inj) (p=0.483). The seroresponses for rubella were 26.7% for MMR SII (ae), 31.3% for MMR II (ae), 46.9% for MMR SII (inj), and 40.0% for MMR II (inj) (p=0.086). The seroresponse to mumps were 31.7% for MMR SII (ae), 25.0% for MMR II (ae), 48.4% for MMR SII (inj), and 53.9% for MMR II (inj) (p=0.002). The difference in the seroresponse of a 4-fold rise from the baseline antibody titers was not statistically significant. Only mild adverse events were noted.

CONCLUSION:

Aerosolized vaccines were as safe and as immunogenic as injected vaccines.

PROTOCOL REGISTRATION:

CMN 2010-005 (National Regulatory Authority).

KEYWORDS:

Aerosolized MMR vaccines; Strain RA 27/3; Strains Edmonston–Zagreb Attenuvax; Strains Leningrad–Zagreb Jeryl Lynn

PMID:
24837512
DOI:
10.1016/j.vaccine.2014.04.031
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center